Dr. Reddy’s Bags Deal For Supply Of Generic Drugs To German Insurer AOK
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After a wait that lasted months, Dr. Reddy's Labs of India has bagged contracts for supplies of seven drugs to top German insurer AOK. AOK had called for bids from generic drug companies for a two-year contract valued at roughly € 2.3 billion ($2.98 billion) by financial analysts
You may also be interested in...
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News
In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.
Generic Imitrex Launch In U.S. Drives Strong Revenue Growth For Dr. Reddy’s
Mumbai - India's Dr. Reddy's Labs posted a 49 percent growth in its third quarter revenues at 18.40 billion rupees ($379 million) with strong sales coming from its generic versions of anti-migraine drug Imitrex (sumatriptan succinate) in the U.S. Dr. Reddy's registered an after tax profit of 1.92 billion rupees ($ 40 million) for the same period against a loss of $ 25 million for the third quarter of 2008